Gonadal Function in Young to Middle Aged HIV-infected Men
Gonadal Function in Young to Middle Aged HIV-infected Men Assessed by Isotopic Dilution-liquid Chromatography-mass Spectrometry (ID-LC-MS/MS) and Chemiluminescent Immunoassay
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Modena, Italy, 41124
- Azienda Ospedaliero - Universitaria di Modena
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male gender
- Age 18-50 years
- HIV-infection
- Ongoing Highly Active Antiretroviral Therapy
Exclusion Criteria:
- Previous treatment with androgens, anti-androgens
- Severe liver insufficiency
- Severe renal insufficiency
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HIV-infected male patients
Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
|
No intervention is provided
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum total testosterone
Time Frame: Assessed only once at the moment of enrollment with liquid chromatography tandem mass spectrometry
|
From blood sample - unit of measurement ng/dL
|
Assessed only once at the moment of enrollment with liquid chromatography tandem mass spectrometry
|
|
Serum total testosterone
Time Frame: Assessed only once at the moment of enrollment with chemiluminiscent immunoassay
|
From blood sample - unit of measurement ng/dL
|
Assessed only once at the moment of enrollment with chemiluminiscent immunoassay
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum free testosterone
Time Frame: Calculated only once at the moment of enrollment
|
Calculated formula (Vermeulen equation)
|
Calculated only once at the moment of enrollment
|
|
Score at IIEF questionnaire
Time Frame: Assessed only once at the moment of enrollment
|
Total score at erectile function domain of IIEF-15 questionnaire
|
Assessed only once at the moment of enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Endocrine System Diseases
- Gonadal Disorders
- Sexual Dysfunctions, Psychological
- Sexual Dysfunction, Physiological
- Slow Virus Diseases
- HIV Infections
- Erectile Dysfunction
- Acquired Immunodeficiency Syndrome
- Hypogonadism
- Eunuchism
Other Study ID Numbers
Other Study ID Numbers
- 15/13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.